Vice President Biden Speaks at Launch of Bloomberg~Kimmel Institute for Cancer Immunotherapy

Editor’s Note: This post was originally featured on the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center blog “Cancer Matters.” The American Association for Cancer Research (AACR) strongly supports this collaboration to establish a new immunotherapy center at Johns Hopkins, and thanks Vice President Biden for his continued commitment to cancer research. As part of his national tour of cancer research institutions, Vice President Biden will deliver remarks at the 2016 AACR Annual Meeting to an audience comprised a large segment of laboratory, translational, and clinical researchers; population scientists; other health care professionals; and patient advocates who are members of the AACR, as well as a national and international audience via a webcast.

From the “Cancer Matters” blog:

Vice President Joe Biden and philanthropist Michael R. Bloomberg at the launch of the Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins University.

Vice President Joe Biden spoke to researchers, medical students, government leaders and others during the dedication of the new Bloomberg~Kimmel Institute for Cancer Immunotherapy. It was founded with gifts of $50 million each from Michael R. Bloomberg and Sidney Kimmel, and $25 million from more than a dozen additional supporters. Read the immunotherapy feature story in Promise and Progress magazine, a news release, re-cap of the dedication event, and our news feature items. Watch the dedication event on Periscope or YouTube.

The news was reported by the Washington Post, Associated Press, STAT News, Baltimore Sun, and many other media outlets. Other organizations also voiced their support: “The American Association for Cancer Research (AACR) is delighted to learn that Johns Hopkins will establish a new immunotherapy center as this institution has on its faculty a number of outstanding leaders in this field who will help to make major advances against cancer, and we congratulate Drew Pardoll, MD, PhD, the institute’s inaugural director, ” said Margaret Foti, PhD, MD (hc), CEO of the AACR. “Immunotherapy has the potential to revolutionize cancer treatment as we know it.  The AACR has long believed that only when all stakeholders collaborate in the quest to conquer cancer will we achieve the vision of making significant advances against cancer in the very near future.”